Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response

References

• Garfinkel D, Laudon M, Nof D, et al. Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 1995;346:541-4
   PubMed Web of Science ®Google Scholar
• Haimov I, Lavie P, Laudon M, et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995;18:598-603
   PubMed Web of Science ®Google Scholar
• Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relation to the response to melatonin replacement therapy. Am J Med 2004;116:91-5
   PubMed Web of Science ®Google Scholar
• Lemoine P, Nir T, Laudon M, et al. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J. Sleep Res. 2007;16:372-80
   PubMed Web of Science ®Google Scholar
• Wade AG, Ford I, Crawford G, et al. Efficacy of prolonged-release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23:2597-605
   PubMed Web of Science ®Google Scholar
• Luthringer R, Muzet M, Zisapel N, et al. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 2009;24:239-49
   PubMed Web of Science ®Google Scholar
• Chesson A, Hartse K, Anderson WM, et al. Practice parameters for the evaluation of chronic insomnia. Sleep 2000;23:237-41
   PubMed Web of Science ®Google Scholar
• Wade AG, Ford I, Crawford G, McConnachie A, et al. Nightly treatment of primary insomnia with prolonged-release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 2010;8:51
   PubMed Web of Science ®Google Scholar
• World Psychiatric Assocation: The Management of Insomnia, Guidelnes for Clinical Practice. 1991
   Google Scholar
• Backhaus J, Junghanns K, Broocks A, et al. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. Psychosom Res 2002;53:737-40
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Ancoli-Israel S, Edinger JD, et al. Recommendations for a standard research assessment of insomnia. Sleep 2006;29:1155-73
   PubMed Web of Science ®Google Scholar
• Bech P, Olsen LR, Kjoller M, et al. Measuring well-being rather than the absence of distress symptoms: a comparison of the SF-36 Mental Health subscale and the WHO-Five Well-Being Scale. Int J Methods Psychiatr Res 2003;12:85-91
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology (rev, 1976), 1976 edn. Kensington: DHEW publication. Biometric Laboratory, George Washington University, US Department of Health, Education and Welfare, 1976
   Google Scholar
• Tyrer P, Murphy S, Riley P. The Benzodiazepine Withdrawal Symptom Questionnaire. J Affect Disord 1990;19:53-61
   PubMed Web of Science ®Google Scholar
• Weyerer S, Dilling H. Prevalence and treatment of insomnia in the community: results from the Upper Bavarian Field Study. Sleep 1991;14:392-8
   PubMed Web of Science ®Google Scholar
• Czeisler CA, Dumont M, Duffy JF, et al. Association of sleep-wake habits in older people with changes in output of circadian pacemaker. Lancet 1992;340:933-6
   PubMed Web of Science ®Google Scholar
• Mirmiran M, Swaab DF, Kok JH, et al. Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. Prog Brain Res 1992;93:151-62; discussion 162-3
   PubMed Web of Science ®Google Scholar
• Hofman MA, Swaab DF. Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res 1994;651:134-42
   PubMed Web of Science ®Google Scholar
• Kunz D, Schmitz S, Mahlberg R, et al. A new concept for melatonin deficit: on pineal calcification and melatonin excretion. Neuropsychopharmacology 1999;21:765-72
   PubMed Web of Science ®Google Scholar
• Zhdanova IV. Comment on ‘Melatonin as a hypnotic: con'. Sleep Med Rev 2005;9:81; discussion 83-4
   PubMed Web of Science ®Google Scholar
• Mahlberg R, Kienast T, Hadel S, et al. Degree of pineal calcification (DOC) is associated with polysomnographic sleep measures in primary insomnia patients. Sleep Med 2009;10:439-45
   PubMed Web of Science ®Google Scholar
• Gorfine T, Assaf Y, Goshen-Gottstein Y, et al. Sleep-anticipating effects of melatonin in the human brain. Neuroimage 2006;31:410-18
   PubMed Web of Science ®Google Scholar
• Gorfine T, Zisapel N. Late evening brain activation patterns and their relation to the internal biological time, melatonin, and homeostatic sleep debt. Hum Brain Mapp 2009;30:541-52
   PubMed Web of Science ®Google Scholar
• Tzischinsky O, Lavie P. Melatonin possesses time-dependent hypnotic effects. Sleep 1994;17:638-45
   PubMed Web of Science ®Google Scholar
• Lockley SW, Skene DJ, James K, et al. Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol 2000;164:R1-6
   PubMed Web of Science ®Google Scholar
• Lewy AJ, Emens JS, Bernert RA, et al. Eventual entrainment of the human circadian pacemaker by melatonin is independent of the circadian phase of treatment initiation: clinical implications. J Biol Rhythms 2004;19:68-75
   PubMed Web of Science ®Google Scholar
• Zisapel N, Tarrasch R, Laudon M. The relationship between melatonin and cortisol rhythms: clinical implications of melatonin therapy. Drug Devel Res 2005;65:119-25
   Web of Science ®Google Scholar
• Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 2006;119:898-902
   PubMed Web of Science ®Google Scholar
• Oaknin-Bendahan S, Anis Y, Nir I, et al. Effects of long-term administration of melatonin and a putative antagonist on the ageing rat. Neuroreport 1995;6:785-8
   PubMed Web of Science ®Google Scholar
• Wu YH, Zhou JN, Van Heerikhuize J, et al. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging 2007;28:1239-47
   PubMed Web of Science ®Google Scholar
• Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep 2009;32:351-60
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Zolpidem F. Clinical Review. http://www.fda.gov/cder/foi/nda/pre96/019908_S000_AmbienTOC.htm. 1992
   Google Scholar
• Ancoli-Israel S, Walsh JK, Mangano RM, et al. Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects. Primary Care Companion J Clin Psychiatry 1999;1:114-20
   PubMedGoogle Scholar
• EMEA. Summary of Product Characteristics for Sonata (zaleplon). http://www.emea.europa.eu/humandocs/Humans/EPAR/sonata/sonata.htm 2007
   Google Scholar
• Mendelson W. Effects of flurazepam and zolpidem on the perception of sleep in insomniacs. Sleep 1995;18:92-6
   PubMed Web of Science ®Google Scholar
• Morgenthaler TI, Silber MH. Amnestic sleep-related eating disorder associated with zolpidem. Sleep Med 2002;3:323-7
   PubMedGoogle Scholar
• Buscemi N, Vandermeer B, Friesen C, et al. The efficacy and safety of drug treatments for chronic insomnia in adults: a meta-analysis of RCTs. J Gen Intern Med 2007;22:1335-50
   PubMed Web of Science ®Google Scholar
• Morin MC. Physiological and pharmacological approaches to treating insomnia: critical issues in assessing their separate and combined effects. Clin Psychol Rev 1996;16:521-42
   Web of Science ®Google Scholar
• Wilson SJ, Nutt DJ, Alford C, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 2010;24:1577-601
   PubMed Web of Science ®Google Scholar